CPHI (China Pharma Holdings, Inc.) Future Price to Earnings

Graphic logo of China Pharma Holdings (CPHI)

Government procurement in China is reducing generic drug margins, weakening the market position of China Pharma Holdings (CPHI). However, stable cash flow is maintained through legacy CNS medications. The mass production of anti-infective and antipsychotic drugs at the company's own plants is confirmed by the projected P/E ratio chart for China Pharma Holdings (CPHI), where the indicator settled at 0.00.

Market Cap to Projected Earnings: China Pharma Holdings, Inc. (CPHI) for 07/04/2022 - 11/18/2026

Metric breakdowns and analytics for China Pharma Holdings (CPHI)

- business market valuation indicators:
Fundamental valuation:CPHI China Pharma Holdings, Inc.
Brand item of China Pharma

This indicator compares the projected business value with the issuer's actual ability to generate cash flow for debt service, excluding subjective management forecasts. By analyzing the future P/E NTM of China Pharma Holdings (CPHI), an investor can see how the robotization of generic production and warehouse automation at China Pharma Holdings (CPHI) reduce costs, directly converting technological efficiency into the fundamental undervaluation or overvaluation of the asset.